Treatment strategies for chemotherapy-induced peripheral neuropathy: Potential role of exercise

Oncology Reviews

Volumn 4, Issue 2, 2010, Pages 117-125

  Wonders, Karen Y ^a   Reigle, Beverly S ^b   Drury, Daniel G ^c  

^a WRIGHT STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c GETTYSBURG COLLEGE   (United States)

Author keywords

Chemotherapy induced peripheral neuropathy; Exercise

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; ALPHA TOCOPHEROL; AMIFOSTINE; BORTEZOMIB; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DIETHYLDITHIOCARBAMIC ACID; DOCETAXEL; EPOTHILONE B; GABAPENTIN; GLUTAMINE; GLUTATHIONE; IFOSFAMIDE; LAMOTRIGINE; LEUKEMIA INHIBITORY FACTOR; NAVELBINE; NIMODIPINE; OXALIPLATIN; PACLITAXEL; PHENYTOIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SURAMIN; THALIDOMIDE; THIOCTIC ACID; VALPROIC ACID; VENLAFAXINE; VINCRISTINE; VINDESINE;

AEROBIC EXERCISE; ANALGESIA; ANXIETY DISORDER; BALANCE DISORDER; BLOOD CLOTTING DISORDER; BLURRED VISION; BRIEF PAIN INVENTORY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DIABETIC NEUROPATHY; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG INDUCED DISEASE; ENDONEURIUM; ENDURANCE TRAINING; EXERCISE; EXERCISE INTENSITY; EXERCISE TOLERANCE; FATIGUE; GAZE; GENE EXPRESSION; GENE OVEREXPRESSION; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERALGESIA; HYPERTENSION; HYPOALGESIA; INSULIN RELEASE; LIFESTYLE MODIFICATION; LIMB SWELLING; MEMORY DISORDER; MOTOR NEUROPATHY; MUSCLE CRAMP; MYALGIA; NAUSEA; NERVE FIBER C; NEUROBIOLOGY; NEUROPATHIC PAIN; NEUROPROTECTION; NON PROFIT ORGANIZATION; OXIDATIVE STRESS; PAIN THRESHOLD; PERIPHERAL NEUROPATHY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RESISTANCE TRAINING; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TINGLING; SLEEP DISORDER; TISSUE BLOOD FLOW; TREMOR; VASODILATATION; VASOPRESSIN RELEASE; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 77954563658     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-010-0044-1     Document Type: Review

References (116)

1. American Cancer Society (2009) Cancer facts & figures 2009. Author, Atlanta, GA
2. National Heart, Lung, and Blood Institute (2008) NHLBI fact book, fiscal year 2007. Author, Bethesda, MD
3. National Cancer Institute (2009) Office of Cancer Survivorship. http://dccps.nci.nih.gov/ocs/researcher-factsheet.pdf. Retrieved 5 December 2009
4. Ganz PA (2007) Cancer survivorship: today and tomorrow. Springer, New York, pp 1-7
5. Lind J (1992) Tumor cell growth and cell kinetics. Semin Oncol Nurs 8(1):3-9
6. Rieger PT (2006) Cancer biology and implications for treatment. Clin J Oncol Nurs 10(4):457-460
7. Honea N, Brant J, Beck SL (2007) Treatment-related symptom clusters. Sem Oncol Nurs 23(2):142-151
8. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9-17
9. Antonine JC, Camdessanche JP (2007) Peripheral nervous system involvement in patients with cancer. Lancet Neurol 6:75-86
10. Kaley TJ, DeAngelis LM (2009) Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 145:3-14
11. Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M et al. (2009) NCCN task force report: management of neuropathy in cancer. J NCCN 7:S-1-28
12. Woolf CJ (2004) Pain: moving from symptom control toward mechanism-speciic pharmacologic management. Ann Intern Med 140:441-445
13. Horowitz SH (2007) The diagnostic workup of patients with neuropathic pain. Med Clin N Am 91:21-30
14. National Health & Medical Research Council (1999) Acute pain management: scientiic evidence. Commonwealth of Australia, Australia
15. Verstappen CP, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs 63(15):1549-1563
16. Visovsky C (2003) Chemotherapy-induced peripheral neuropathy. Cancer Investig 21(3):439-451
17. Wolf CJ, Mannion RJ (1999) Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353:1959-1964
18. Reyes-Gibby CC, Marrow PK, Buzdar A, Shete S (2009) Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain 10:1146-1150
19. Tulub AA, Stefanov VE (2001) Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanisms of anti-tumor activity of platinum complexes. Int J Biol Macromol 28:191-198
20. Benoit E, Brienza S, Dubois JM (2006) Oxaliplatin, an anti-cancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons. Gen Physiol Biophys 25:263-276
21. Scadding JW, Kiltzenburg M (2006) Painful peripheral neuropathies. In: McMahon SB, Koltzenburg M (eds) Wall and Melzacks, textbook of pain, 5th edn. Elsevier Churchill Livingstone, Philadelphia, PA, pp 973-999
22. Jensen TS, Baron R (2003) Translation of symptoms and signs into mechanisms of neuropathic pain. Pain 102:13-18
23. Ahmad M, Goucke CR (2002) Management strategies for the treatment of neuropathic pain in the elderly. Drug Aging 19:929-945
24. Bakitas MA, Smith E, Cohen J, Fadul C (2004) Measurement issues in chemotherapy-induced peripheral neuropathy. In: Paper presented at the international conference on the mechanisms and treatment of neuropathic pain, Bermuda, November 4-6, 2004
25. Grothey A (2007) Oxaliplatin-safety proile: neurotoxicity. Semin Oncol 30(suppl 15):5-13
26. Tolle T, Zu Z, Sadosky AB (2006) Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications 20:26-33
27. Zelman D, Core M, Dukes E, Tai K, Brandenburg N (2005) Validation of a modiied version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage 29:401-410 (Pubitemid 40602521)
28. Jensen MP, Hoffman AJ, Cardenas DD (2005) Chronic pain in individuals with spinal cord injury: a survey and longitudinal study. Spinal Cord 43:704-712
29. Bergbom-Engberg I, Grondahl G, Thibom K (1995) Patients' experiences of herpes zoster and postherpetic neuralgia. J Adv Nurs 21:427-433
30. Galer B, Gianas A, Jensen M (2000) Painful diabetic polyneu-ropathy: epidemiology, pain, description, and quality of life. Diabetes Res Clin Pract 47:123-128
31. Tasmuth T, von Smitten K, Hietanen P et al (1995) Pain and other symptoms after different treatment modalities of breast cancer. Ann Oncol 6:453-459
32. Flier J, Van Muiswinkel FL, Jongenen CA et al (2002) The neuroprotective antioxidant alpha-lipoic acid induces detoxica-tion enzymes in cultured astroglail cells. Free Radic Res 36:695-699
33. Bianchi G, Vitali G, Caraceni A et al (2005) Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced peripheral neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41:1746-1750
34. Tankova T, Cherninkova S, Koev D (2005) Treatment for diabetic mononeuropathy with alpha-lipoic acid. Int J Clin Pract 59:645-650
35. Eckel F, Schmelz R, Adelsberger H et al (2002) Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study. Dtsch Med Wochenchr 127:78-82
36. Sindrup S, Jensen T (1999) Eficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83:389-400
37. Goodman LS, Limbird LE, Milinoff PB et al (eds) (1996) Goodman and Gilman's: the pharmacological basis of therapeutics, 9th edn. McGraw-Hill Professional, New York
38. Jensen TS (2002) Anticonvulsants in neuropathic pain. Eur J Pain 6(Suppl A):61-68
39. Backonja M, Beydoun A, Edwards KR et al (1978) Gabapentin for the symptomatic treatment of painful neuropathy. J Assoc Physicians India 26(5):403-406
40. Rao RD, Michalak JD, Sloan JA et al (2007) Eficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy. Cancer 110:2110-2118
41. Gatti G, Bonomi I, Jannuzzi G et al (2000) The new antiepileptic drugs: pharmacological and clinical aspects. Curr Pharm Des 6:839-860
42. Gwag BJ, Sessler FM, Robine V et al (1997) Endogenous glu-tamate levels regulate nerve growth factor mRNA expression in the rat denate gyrus. Mol Cells 7:425-430
43. De Santis S, Pace A, Bove L et al (2000) Patients treated with antitumor drugs displaying neurological deicits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 6:90-95
44. Bailey HH, Gipp JJ, Ripple M, Wilding G, Mulcahy RT (1992) Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res 52:5115-5118
45. Britten RA, Green JA, Warenius HM (1992) Cellular glutathi-one (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radiat Oncol Biol Phys 24:527-531
46. Joncourt F, Oberli-Schrammli AE, Stadler M et al (1995) Patterns of drug resistance parameters in adult leukemia. Leuk Lymph 17:101-109
47. Perry RR, Mazetta JA, Levin M, Barranco SC (1993) Gluta-thione levels and variability in breast tumors and normal tissue. Cancer 72:783-787
48. Redmond SM, Joncourt F, Buser K et al (1991) Assessment of P-glycoprotein, glutathione-based detoxidying enzymens and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 51:2092-2097
49. Mulder TP, Manni JJ, Roelofs HM, Peters WH, Wiersma A (1995) Glutathione S-transferases and glutathione in human head and neck cancer. Carcinogenesis 16:619-624
50. Cook JA, Pass HI, Iype SN et al (1991) Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue. Cancer Res 51:4287-4294
51. Suzuki T, Nishio K, Tanabe S (2001) The MRP family and anticancer drug metabolism. Curr Drug Metab 2:367-377
52. Kawai H, Kiura K, Tabata M et al (2002) Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. Lung Cancer 35:305-314 (Pubitemid 34158665)
53. Smyth JF, Bowman A, Parren T et al (1997) Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomized trial. Ann Oncol 8:569-573
54. Cascinu S, Cordella L, Del Ferro E et al (1995) Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 13:26-32
55. Eisenberg E, Lurie Y, Braker C et al (2001) Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 57:505-509
56. Canavero S, Bonicalz V (1996) Lamotrigine control of central pain. Pain 68:179-181
57. Renno SI, Rao RD, Sloan J et al (2006) The eficacy of lamo-trigine in the management of chemotherapy-induced peripheral neuropathy: a phase III randomized, double blind, placebo-controlled NCCTG trial, N01C3. J Clin Oncol 24(185):8530
58. Saudek CD, Werns S, Reidenberg MM (1977) Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 22(2):196-199
59. Tremont-Lukats IW, Megeff C, Backonja MM (2000) Anti-convulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs 60:1029-1052
60. Wilson RH, Lehky T, Thomas RR et al (2002) Acute oxalipl-atin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767-1774
61. Traber MG (2006) Vitamin E. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins R (eds) Modern nutrition in health and disease, 10th edn. Lippincott Williams & Wilkins, Baltimore, pp 396-411
62. Argyriou AA, Chroni E, Koutras A et al (2005) Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64:26-31 (Pubitemid 40082932)
63. Pace A, Savarese A, Picardo M et al (2003) Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 21:927-931
64. Jacobs EJ, Henion AK, Briggs PJ et al (2002) Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am J Epidemiol 156:1002-1010
65. Moore DH, Donnelly J, McGuire WP et al (2003) Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neuropathy: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 21:4207-4213
66. Nelson DF, Gillespie BW, Diener MD et al (1984) Is misoni-dazole neurotoxicity altered by the use of phenytoin and/or dexamethasone in ROTG 79-18 and RTOG 79-16? Int J Radiat Oncol Biol Phys 10:1731-1734
67. Bergouignan FX, Vital C, Henry P et al (1988) Disulfiram neuropathy. J Neurol 235:382-383
68. Lehky TJ, Leonard GD, Wilson RH et al (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29:387-392
69. Davis ID, Kiers L, MacGregor L et al (2005) A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 11:1890-1898
70. Hamers FP, van der Hoop RG, Steerenburg PA et al (1991) Putative neurotrophic factors in the protection of cisplatin-induced peripheral neuropathy in rats. Toxicol Appl Pharmacol 111:514-522
71. Roberts JA, Jenison EL, Kim K et al (1997) A randomized, multicenter, double-blind, placebo-controlled, dose-inding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 67:172-177
72. Markes M, Brockow T, Resch KL (2008) Exercise for women receiving adjuvant therapy for breast cancer (Review). The Cochrane Collection, Published by Wiley Ltd in The Cochrane Library, Issue 4
73. Irwin ML, Crumley D, McTiernan A, Bernstein L, Baumgartner R, Gilliland FD, Kriska A, Ballard-Barbash R (2003) Physical activity levels before and after a diagnosis of breast carcinoma: the Healthy Eating, Activity, and Lifestyle (HEAL) study. Cancer 97(7):1746-1757
74. Herrero F, San Juan AF, Fleck SJ, Balmer J, Perez M, Canete S, Earnest CP, Foster C, Lucia A (2005) Combined aerobic and resistance training in breast cancer survivors: a randomized, controlled pilot trial. Int J Sports Med 26(4):294-302
75. Aitken DR, James AG (1997) Seromas and physiotherapy after mastectomy. Ann Surg Oncol 4(4):293-297
76. Schneider CM, Dennehy CA, Roozeboom M, Carter SD (2002) A model program: exercise intervention for cancer rehabilitation. Integr Cancer Ther 1:76-82
77. Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R (2007) Effects of supervised exercise training on cardiopulmo-nary function and fatigue in breast cancer survivors during and after treatment. Cancer 110:918-925 (Pubitemid 47257672)
78. Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R (2007) Exercise training manages cardiopulmonary function and fatigue during and following cancer treatment in male cancer survivors. Integr Cancer Ther 6(3):235-241 (Pubitemid 47301117)
79. Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R (2007) Cancer treatment-induced alterations in muscular itness and quality of life: The role of exercise training. Ann Oncol 18:1957-1962
80. Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, Fallucca F (2006) Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Its Complicat 20:216-223
81. Richardson J, Sandman D, Vela S (2001) A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. Arch Phys Med Rehabil 82:205-209
82. Tesfaye S, Harris ND, Wilson RM, Ward JD (1992) Exercise-induced conduction velocity increment: a marker of impaired peripheral nerve blood flow in diabetic neuropathy. Diabetologia 35:155-159
83. Lindeman E, Leffers P, Spaans F, Drukker J, Reulen J, Ker-ckhoffs M, Koke A (1995) Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: a randomized clinical trial. Arch Phys Med Rehabil 76(7):612-620
84. Kilmer DD, McCroy MA, Wright NC, Aitkens SG, Bernauer EM (1994) The effect of a high resistance exercise program in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 75(5):560-563
85. Aitkens SG, McCrory MA, Kilmer DD, Bernauer EM (1993) Moderate resistance exercise program: its effect in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 74(7):711-715
86. Lindeman E, Leffers P, Reulen J, Spaans F, Drukker J (1998) Quadriceps strength and timed motor performances in myotonic dystrophy, Charcot-Marie-Tooth disease, and healthy subjects. Clin Rehabil 12(2):127-135
87. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM (2004) Diabetic somatic neuropathies. Diabetes Care 27:1458-1486
88. Yong J, Loukianov E, Loukianova T, Jones LR, Periasamy M (1999) SERCA1a can functionally substitute for SERCA2a in the heart. Am J Physiol 276:H89-H97
89. Wu KD, Lee WS, Wey J, Bungard D, Lytton J (1995) Localization and quantiication of endoplasmic reticulum Ca2+- ATPase isoform transcripts. Am J Physiol 269:C775-C784. Cell Physiol 38
90. Kleuber KM, Feczko JD (1994) Ultrastructural, histochemical, and morphometric analysis of skeletal muscle in a murine model of type I diabetes. Anat Rec 239:18-34
91. Racz G, Szabo A, Ver A, Zador E (2009) The slow sarco/endoplasmic reticulum Ca2+-ATPase declines independently of slow myosin in soleus muscle of diabetic rats. Acta Biochim Pol 56:487-493
92. ® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61(suppl 2):14-21
93. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212
94. Samantha A, LeVea CM, Dougall WC, Quian X, Greene MI (1994) Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci USA 91:1711-1715
95. McGuire JF, Ruen S, Siegfreid E, Wright DE, Dobrowsky RT (2009) Caveolin-1 and altered neuregulin signaling contribute to the pathophysiological progression of diabetic peripheral neuropathy. Diabetes 58:2677-2686
96. Yatime L, Buch-Pedersen MJ, Musgaard M et al (2009) P-type ATPases as drug targets: tools for medicine and science. Bio- physica Acta 1787:207-220
97. ® immunotherapy in metastatic breast cancer. Oncology 61(suppl 2):58-66
98. Feldman AM, Lorell BH, Reis SE (2000) Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 102:272-274
99. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100(15):8933-8938
100. Gustafsson T, Puntschart A, Kaijser L, Lansson E, Sundberg CJ (1999) Exercise-induced expression of angiogenesis-related transcription and growth factors in human skeletal muscle. Am J Physiol 276:H679-H685 (Pubitemid 29100638)
101. Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, Harrison DG (2000) Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest 105:1631-1639
102. Wisloff U, Loennechen JP, Falck G, Veisvag V, Currie S, Smith G, Ellingsen O (2001) Increased contractility and calcium sensitivity in cardiac myocytes isolated from endurance trained rats. Cardiovasc Res 50:495-508
103. Tate CA, Taffet GE, Hudson EK, Blaylock SL, McBride RP, Michael LH (1990) Enhanced calcium uptake of cardiac sar-coplasmic reticulum in exercise-trained old rats. Am J Physiol 258:H431-H435. Heart Circ Physiol 27
104. Tate CA, Helgason T, Hyek MF, McBride RP, Chen M, Richardson MA, Taffet GE (1996) SERCA2a and mitochondrial cytochrome oxidase expression are increased in hearts of exercise-trained old rats. Am J Physiol 271:H68-H72. Heart Circ Physiol 40
105. Wonders KY, Hydock DS, Greufe S, Schneider CM, Hayward R (2009) Endurance training preserves cardiac function in rats receiving doxorubicin and the HER2-inhibitor GW2974. Cancer Chemother Pharmacol 64(6):1105-1113
106. Obrosova IG, Drel VR, Pacher P et al (2005) Oxidative-nitro-sative stress and poly(ADP-Ribose) polymerase PPARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes 54:3435-3441
107. Obrosova IG, Drel VR, Oltman CL et al (2007) Rose of nitro-sative stress in early neuropathy and vascular dysfunction in streptozotcin-diabetic rats. Am J Physiol Endocrinol Metab 293:E1645-E1655
108. KoltynKF, Wertz AL, GardinerRLetal (1996) Perception ofpain following aerobic exercise. Med Sci Sports Exerc 28:1418-1421
109. Gurevich M, Kohn PM, Davis C (1994) Exercise-induced analgesia and the role of reactivity in pain sensitivity. J Sports Sci 12:549-559
110. Sternberg WF, Bokat C, Kass L et al (2001) Sex-dependent components of the analgesia produced by athletic competition. Pain 94:65-74
111. Sternberg WF, Bailin D, Grant M et al (1998) Competition alters the perception of noxious stimuli in male and female athletes. Pain 76:231-238
112. Haier RJ, Quaid K, Mills JSC (1981) Naloxone alters pain perception after jogging. Psychiatry Res 5:231-232
113. Koltyn KF, Arbogast RW (1998) Perception of pain after resistance exercise. Br J Sports Med 32:20-24
114. Carter GT, Kikuchi N, Abresch RT, Walsh SA, Horasek S, Fowler WM (1994) Effects of exhaustive concentric and eccentric exercise on murine skeletal muscle. Arch Phys Med Rehabil 75:555-559
115. Carter GT, Abresch RT, Fowler WM (2002) Adaptations to exercise training and contraction-induced muscle injury in animal models of neuromuscular disease. Am J Phys Med Rehabil 81(suppl):S151-S161
116. Breslin E, Booth J, Lord B et al (1993) Respiratory responses to unsupported arm exercise (UAE) in Charcot Marie Tooth (CMT) [abstract]. American Thoracic Society. Am Rev Respir Dis 147:A532